Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

MEITAV INVESTMENT HOUSE LTD (MTAV)

  • Business News
  • March 27, 2026, 05:48 UTC
  • 2
  • 1 comments

Private offering

Market reaction Comment Full text

BANK HAPOALIM B.M. (POLI)

  • Business News
  • March 27, 2026, 05:47 UTC
  • 0
  • 1 comments

Dormant shares

Market reaction Comment Full text

MEITAV INVESTMENT HOUSE LTD (MTAV)

  • Business News
  • March 27, 2026, 05:15 UTC
  • 0
  • 1 comments

Events and transactions

Market reaction Comment Full text

AZORIM-INVESTMENT, DEVELOPMENT & CONSTRUCTION CO. LTD. (AZRM)

  • Business News
  • March 27, 2026, 04:48 UTC
  • 0
  • 1 comments

Dividend in kind

Market reaction Comment Full text

AZORIM-INVESTMENT, DEVELOPMENT & CONSTRUCTION CO. LTD. (AZRM)

  • Business News
  • March 27, 2026, 04:46 UTC
  • 3
  • 1 comments

dividend

Market reaction Comment Full text

AZORIM-INVESTMENT, DEVELOPMENT & CONSTRUCTION CO. LTD. (AZRM)

  • Business News
  • March 27, 2026, 04:23 UTC
  • 3
  • 1 comments

Management and officers – staffing as of 27.3.26

Market reaction Comment Full text

AZORIM-INVESTMENT, DEVELOPMENT & CONSTRUCTION CO. LTD. (AZRM)

  • Business News
  • March 27, 2026, 04:19 UTC
  • 3
  • 1 comments

The company’s liability position as of 31.12.25, by maturity dates

Market reaction Comment Full text

AZORIM-INVESTMENT, DEVELOPMENT & CONSTRUCTION CO. LTD. (AZRM)

  • Business News
  • March 27, 2026, 04:17 UTC
  • 3
  • 1 comments

Periodic and annual report for 2025

Market reaction Comment Full text

ZENAS BIOPHARMA, INC. (ZBIO)

  • Business News
  • March 27, 2026, 04:12 UTC
  • 4
  • 1 comments

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Market reaction Comment Full text

GCL GLOBAL HOLDINGS LTD (GCL)

  • Business News
  • March 27, 2026, 03:54 UTC
  • 3
  • 1 comments

Groupe Colabor Inc. fait le point sur son processus de vente et de sollicitation d’investissements

Market reaction Comment Full text
  • Previous
  • 637
  • 638
  • 639
  • 640
  • 641
  • Next

Search

News categories

  • Technical Exchange News(11766)
  • Event(4289)
  • SEC News(235969)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(143396)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin